| [1] |
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int, 2009, 76(Suppl 113): S50-S99.
|
| [2] |
Couttenye MM,D′Haese PC,Van Hoof VO, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients[J]. Nephrol Dial Transplant, 1996, 11(6): 1065-1072.
|
| [3] |
Brandenburg VM,Ketteler M,Rodriguez M. Ten years of progress in our understanding of uremic vascular calcification and disease: a decade summarized in 20 steps[J]. Kidney Int Suppl, 2011, 1(4): 116-121.
|
| [4] |
Goodman WG,London G,Amann K, et al. Vascular calcification in chronic kidney disease[J]. Am J Kidney Dis, 2004, 43(3): 572-579.
|
| [5] |
Demer LL,Tintut Y. Vascular calcification: pathobiology of multifaceted disease[J]. Circulation, 2008, 117(22): 2938-2948.
|
| [6] |
Moe SM,Chen NX. Pathophysiology of vascular calcification in chronic kidney disease[J]. Circ Res, 2004, 95(6): 560-567.
|
| [7] |
Shioi A,Nishizawa Y. Vascular calcification in chronic kidney disease: pathogenesis and clinical implications[J]. J Ren Nutr, 2009, 19(1): 78-81.
|
| [8] |
Brandi L. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis[J]. Dan Med Bull, 2008, 55(4): 186-210.
|
| [9] |
Koizumi M,Komaba H,Fukagawa M. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis[J]. Contrib Nephrol, 2013, 180: 110-123.
|
| [10] |
Goodman WG,Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics[J]. Kidney Int, 2008, 74(3): 276-288.
|
| [11] |
Mendoza FJ,Lopez I,Canalejo R, et al. Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats[J]. Am J Physiol Renal Physiol, 2009, 296(3): F605-F613.
|
| [12] |
Cozzolino M,Lu Y,Finch J, et al. p21(WAF1) and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium[J]. Kidney Int, 2001, 60(6): 2109-2117.
|
| [13] |
Chudek J,Ritz E,Kovacs G. Genetic abnormalities in parathyroid nodules of uremic patients[J]. Clin Cancer Res, 1998, 4(1): 211-214.
|
| [14] |
Drueke TB,Massy ZA. Changing bone patterns with progression of chronic kidney disease[J]. Kidney Int, 2016, 89(2): 289-302.
|
| [15] |
Malluche HH,Mawad HW,MonierFaugere MC. Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patients[J]. J Bone Miner Res, 2011, 26(6): 1368-1376.
|
| [16] |
Block GA,Klassen PS,Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis[J]. J Am Soc Nephrol, 2004, 15(8): 2208-2218.
|
| [17] |
Moe SM,Drueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product[J]. Am J Nephrol, 2003, 23(6): 369-379.
|
| [18] |
Tentori F,Blayney MJ,Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)[J]. Am J Kidney Dis, 2008, 52(3): 519-530.
|
| [19] |
Floege J. Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them?[J]. Nephrol Dial Transplant, 2008, 23(10): 3050-3052.
|
| [20] |
Barreto FC,Barreto DV,Moyses RM, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients[J]. Kidney Int, 2008, 73(6): 771-777.
|
| [21] |
Cohen-Solal ME,Boudailliez B,Sebert JL, et al. Comparison of intact, mid region and carboxyterminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients[J]. J Clin Endocrinol Metab, 1991, 73(3): 516-524.
|
| [22] |
Quarles LD,Lobaugh B,Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia[J]. J Clin Endocrinol Metab, 1992, 75(1): 145-150.
|
| [23] |
Wang M,Hercz G,Sherrard DJ, et al. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminium toxicity[J]. Am J Kidney Dis, 1995, 26(5): 836-844.
|
| [24] |
Bellasi A,Feramosca E,Muntner P, et a1. Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients[J]. Kidney Int, 2006, 70(9): 1623-1628.
|
| [25] |
Bender FH,Bernardini J,Piraino B. Calcium mass transfer with dialysate containing 1.25 and1.75 mmol/L calcium in peritoneal dialysis patients[J]. Am J Kidney Dis, 1992, 20(4): 367-371.
|
| [26] |
Weinreich T,Ritz E,Passlick-Deetjen J. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: Effects on bone mineral metabolism[J]. Pert Dial Int, 1996, 16(3): 260-268.
|
| [27] |
Brandi L,Melsen PK,Bro S, et a1. Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol/L) on secondary hyperparathyroidism in patients on CAPD[J]. J Inter Med, 1998, 244(2): 121-131.
|
| [28] |
Amstrong A,Beer J,Noonan K, et a1. Reduced calcium dialysate in CAPD patients: Eficacy and limitations[J]. Nephrol Dial Transplant, 1997, 12(6): 1223-1228.
|
| [29] |
Katopodis KP,Koliousi EL,Andrikos EK, et al. Magnesium homeostasis in patients undergoing continuous ambulatory peritoneal dialysis: role of the dialysate magnesium concentration[J]. Artif Organs, 2003, 27(9): 853-857.
|
| [30] |
Navarro JF,Mora C,Garcia J, et al. Hypermagnesemia in continuous ambulatory peritoneal dialysis patients[J]. Perit Dial Int, 1998, 18(1): 77-80.
|
| [31] |
Cho MS,Lee KS,Lee YK, et al. Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate[J]. Korean J Intern Med, 2002, 17(2): 114-121.
|
| [32] |
Mehrotra R,Kermah DA,Salusky IB, et al. Chronic kidney disease, hypovitaminosis D and mortality in the United States[J]. Kidney Int, 2009, 76(9): 977-983.
|
| [33] |
Wang AY,Lam CW,Sanderson JE, et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study[J]. Am J Clin Nutr, 2008, 87: 1631-1638.
|
| [34] |
Aloni Y,Shany S,Chaimovitz C. Losses of 25-hydroxyvitamin in peritoneal fluid: possible mechanism for bone disease in uremic patients treated with chronic ambulatory peritoneal dialysis[J]. Miner Electrolyte Metab, 1983, 9(2): 82-86.
|
| [35] |
Sahin G,Kirli I,Sirgamul B, et al. Loss via peritoneal fluid as a factor for low 25(OH)D3 level in peritoneal dialysis patients[J]. Int Urol Nephrol, 2009, 41(4): 989-996.
|
| [36] |
Rodriguez-Ortiz ME,Canalejo A,Herencia C, et al. Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration[J]. Nephrol Dial Transplant, 2014, 29(2): 282-289.
|
| [37] |
Evenepoel P,Selgas R,Caputo F, et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis[J]. Nephrol Dial Transplant, 2009, 24(1): 278-285.
|
| [38] |
Zhai CJ,Yu XS,Sun QL, et al. Effect of lanthanum carbonate versus calcium-based phosphate binders in dialysis patients: a meta-analysis[J]. Clin Nephrol, 2014, 82(6): 372-378.
|
| [39] |
Hutchison AJ,Maes B,Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a3-year study[J]. Nephron Clin Pract, 2006, 102(2): c61-c71.
|
| [40] |
Hutchison AJ,Barnett ME,Krause R, et al. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment[J]. Nephron Clin Pract, 2008, 110(1): c15-c23.
|
| [41] |
Yokoyama K,Hirakata H,Akiba T, et al. Ferric citrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD[J]. Clin J Am Soc Nephrol, 2014, 9(3): 543-552.
|
| [42] |
Yokoyama K,Akiba T,Fukagawa M, et al. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis[J]. J Renal Nutr, 2014, 24(4): 261-267.
|
| [43] |
Iida A,Kemmochi Y,Kakimoto K, et al. Ferric citrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification[J]. Am J Nephrol, 2013, 37(4): 346-358.
|
| [44] |
Locatelli F,Spasovski G,Dimkovic N, et al. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study[J]. Nephrol Dial Transplant, 2014, 29(5): 1061-1073.
|
| [45] |
Eto N,Miyata Y,Ohno H, et al. Nicotinamide prevents the development of hyperphosphatemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure[J]. Nephrol Dial Transplant, 2005, 20(7): 1378-1384.
|
| [46] |
Jamaluddin EJ,Gafor AH,Yean LC, et al. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism[J]. Clin Exp Nephrol, 2014, 18(3): 507-514.
|
| [47] |
Akizawa T,Akiba T,Hirakata H, et al. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism[J]. Ther Apher Dial, 2015, 19(3): 225-234.
|
| [48] |
Li D,Shao L,Zhou H, et al. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis[J]. Endocrine, 2013, 43(1): 68-77.
|
| [49] |
Yamada S,Tokumoto M,Taniguchi M, et al. Two years of cinacalcet hydrochloride treatment decreased parathyroid gland volume and serum parathyroid hormone level in hemodialysis patients with advanced secondary hyperparathyroidism[J]. Ther Apher Dial, 2015, 19(4): 367-377.
|
| [50] |
Hong YA,Cho YS,Kim SW, et al. Diameter of parathyroid glands measured by computed tomography as a predictive indicator for response to cinacalcet in dialysis patients with secondary hyperparathyroidism[J]. Kidney Blood Press Res, 2015, 40(3): 277-287.
|
| [51] |
Martin KJ,Bell G,Pickthorn K, et al. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects[J]. Nephrol Dial Transplant, 2014, 29(2): 385-392.
|
| [52] |
Martin KJ,Pickthorn K,Huang S, et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients[J]. Kidney Int, 2014, 85(1): 191-197.
|
| [53] |
Henley C 3rd,Yang Y,Davis J, et al. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion[J]. J Pharmacol Exp Ther, 2011, 337(3): 681-691.
|
| [54] |
Neagoe RM,Mircea M,Voidǎzan S, et al. Subtotal parathyroidectomy versus total parathyroidectomy with autotransplant in secondary hyperparathyroidism, a single-centre prospective cohort of 43 patients[J]. Endokrynol Pol, 2016, 67(2): 202-209.
|
| [55] |
Yang J,Hao R,Yuan L, et al. Value of dual-phase (99m)Tc-sestamibi scintigraphy with neck and thoracic SPECT/CT in secondary hyperparathyroidism[J]. Am J Roentgenol, 2014, 202(1): 180-184.
|